Pulmonary Embolism
Conditions
Keywords
Rivaroxaban, JNJ39039039, Pulmonary embolism
Brief summary
The purpose of the study is to evaluate that low risk Pulmonary Embolism (PE) participants who are discharged from the Emergency Department (ED) to the home environment and treated with rivaroxaban as outpatients have fewer total days in the hospital for bleeding and/or venous thromboembolism (VTE) events through Day 30 compared to participants who are treated with initial hospitalization and standard-of-care.
Detailed description
This is a randomized (study medication is assigned by chance), open-label (all people know the identity of the intervention), parallel-group, multicenter (study conducted at multiple sites) study to evaluate that low risk PE participants who are discharged from the ED and treated with rivaroxaban compared to participants who are treated with initial hospitalization and standard-of-care. The study consists of a Screening and Randomization Period, followed by a 90-day open-label treatment period, and an end of study/early withdrawal (EOS) visit. The duration of study participation for each participant is approximately 3 months. The participants will be randomized in a 1:1 ratio to one of two treatments. Safety will be monitored during the study.
Interventions
DRUGRivaroxaban
Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.
DRUGStandard-of-care
Standard-of-care as per local protocol and defined by the medical team caring for the participant.
Sponsors
Bayer
Janssen Scientific Affairs, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have confirmed acute symptomatic Pulmonary Embolism (PE) with or without symptomatic deep vein thrombosis (DVT) * A PE participant diagnosed in the Emergency Department (ED) who is deemed to be at low risk of clinical deterioration as determined by the Hestia criteria * Have no contraindications to and be able to complete randomized treatment and all study assessments * Have a life expectancy of at least 6 months * Must be willing and able to adhere to the prohibitions and restrictions specified in this protocol
Exclusion criteria
* Having received any Combined P-gp (P-glycoprotein) and strong CYP3A4 (Cytochrome P450) inhibitors (such as but not limited to ketoconazole, telithromycin or protease inhibitors) use within 4 days before randomization, or planned use during the study. Itraconazole use within 7 days before randomization or planned use during the study * Having received any Combined P-gp and strong CYP3A4 inducers (such as but not limited to rifampin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, or St. John's Wort) use within 2 weeks before randomization or planned use during the study * Who Has contraindications to the use of any anticoagulant therapy (example, bleeding diathesis, history of gastrointestinal bleeding within 1 year or coagulopathy documented at Screening) * Who Has known allergies, hypersensitivity, or intolerance to rivaroxaban or its excipients * Woman who is pregnant, or breast-feeding, or planning to become pregnant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Duration of Hospitalization | Up to Day 30 | Mean number of days of initial inpatient hospitalization (beginning from randomization to discharge from the hospital) plus any subsequent hospitalization(s) related to bleeding and/or venous thromboembolism (VTE) events up to 30 days were calculated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Reoccurrence of Symptomatic Venous Thromboembolism Event (VTE) (Composite of Recurrent PE, New or Recurrent DVT) or VTE-related Death | Up to 7, 14, 30, and 90 Days | Reoccurrence of symptomatic, objectively confirmed VTE, defined as recurrent pulmonary embolism (PE) or new or recurrent deep vein thrombosis (DVT) (including symptomatic upper extremity DVT) or VTE related death were analyzed. |
| Percentage of Participants With Number of Unplanned Hospital Visits or Physician Office for VTE Symptoms and/or Bleeding | Up to 7, 14, 30 and 90 Days | Percentage of participants of unplanned hospitalization for VTE symptoms or bleeding-related hospital or physician visits were analyzed. |
| Mean Combined Duration of Initial and Subsequent Emergency Department (ED) Hospitalization for Any Reason | Up to 30 and 90 Days | Mean combined duration of Initial and subsequent ED Stay and hospitalization for any reason within 30 and 90 days from randomization was analyzed. |
| Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Day 90 | ACTS is defined as a validated measure for assessing treatment satisfaction. The ACTS comprised of 2 subscales: Burdens (13 items: Item 1 to 13 \[how much of limitation from taking part in vigorous physical activities, limitation from usual activities, bothered by bruising, bothered to avoid other medicines, limitation to diet, daily hassle, occasional hassle, difficult to follow treatment, time-consuming, worrying, frustrating, burden, negative impact on life respectively) and Benefits (4 items: Items 14 to 17 for evaluating confidence, reassurance, satisfaction, positive impact respectively) as a result of anti-clot treatment. The treatment experience scores ranged from 'Not at all' to 'Extremely' on a 5-point Likert scale (psychometric rating); higher scores indicate greater satisfaction with treatment. |
| Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Day 7 | The Satisfaction to Site-of-Care Questionnaire (standard-of-care versus early discharge on rivaroxaban therapy) was administered after 7 days on anticoagulant therapy. Satisfaction to Site-of-Care (hospitalization versus home care) rates the participant's level of satisfaction to care and location with care received as well as preference to location of care provided. Participants rated the 3 items of this scale of 1=Very satisfied; 2=Quite satisfied; 3=Neither; 4=Quite dissatisfied; and 5=Very dissatisfied for satisfaction questions and for the 1 preference question responses included 1=In the hospital; 2=In the community; and 3=No preference. Higher score indicates more level of satisfaction. |
Countries
United States
Participant flow
Pre-assignment details
Of the 300 participants screened, 114 participants were randomized (51 to rivaroxaban group and 63 participants in the standard-of-care group) and 112 participants were treated and received at least 1 dose of study agent.
Participants by arm
| Arm | Count |
|---|---|
| Rivaroxaban Participants received rivaroxaban 15 milligram (mg) twice daily up to Day 21 orally followed by rivaroxaban 20 mg once daily up to Days 90 orally. | 51 |
| Standard-of-care Participants received local Standard-of-care as per local protocol and is defined by the medical team caring for participants. | 63 |
| Total | 114 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 4 | 0 |
| Overall Study | Lost to Follow-up | 3 | 4 |
| Overall Study | Other | 0 | 1 |
| Overall Study | Protocol Violation | 0 | 1 |
| Overall Study | Withdrawal by Subject | 0 | 2 |
Baseline characteristics
| Characteristic | Rivaroxaban | Standard-of-care | Total |
|---|---|---|---|
| Age, Continuous | 49.1 years STANDARD_DEVIATION 13.27 | 47.6 years STANDARD_DEVIATION 17.22 | 48.3 years STANDARD_DEVIATION 15.53 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 2 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 47 Participants | 60 Participants | 107 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 2 Participants | 1 Participants | 3 Participants |
| Race/Ethnicity, Customized Asian | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Black or African American | 20 Participants | 14 Participants | 34 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 2 Participants | 2 Participants | 4 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 47 Participants | 60 Participants | 107 Participants |
| Race/Ethnicity, Customized Other | 1 Participants | 1 Participants | 2 Participants |
| Race/Ethnicity, Customized White | 29 Participants | 48 Participants | 77 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 20 Participants | 14 Participants | 34 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) White | 29 Participants | 48 Participants | 77 Participants |
| Region of Enrollment UNITED STATES | 51 Participants | 63 Participants | 114 Participants |
| Sex: Female, Male Female | 27 Participants | 32 Participants | 59 Participants |
| Sex: Female, Male Male | 24 Participants | 31 Participants | 55 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 49 | 0 / 63 |
| other Total, other adverse events | 15 / 49 | 13 / 63 |
| serious Total, serious adverse events | 5 / 49 | 7 / 63 |
Outcome results
Primary
Mean Duration of Hospitalization
Mean number of days of initial inpatient hospitalization (beginning from randomization to discharge from the hospital) plus any subsequent hospitalization(s) related to bleeding and/or venous thromboembolism (VTE) events up to 30 days were calculated.
Time frame: Up to Day 30
Population: The intention to treat analysis set (ITT) included all participants who were randomized into the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Rivaroxaban | Mean Duration of Hospitalization | 0.191 Days | Standard Deviation 0.6862 |
| Standard-of-care | Mean Duration of Hospitalization | 1.393 Days | Standard Deviation 1.9642 |
p-value: <0.000195% CI: [-1.73, -0.674]t-test
Secondary
Mean Combined Duration of Initial and Subsequent Emergency Department (ED) Hospitalization for Any Reason
Mean combined duration of Initial and subsequent ED Stay and hospitalization for any reason within 30 and 90 days from randomization was analyzed.
Time frame: Up to 30 and 90 Days
Population: The ITT included all participants who were randomized into the study.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Rivaroxaban | Mean Combined Duration of Initial and Subsequent Emergency Department (ED) Hospitalization for Any Reason | Within 30 Days | 0.679 Days | Standard Deviation 2.0894 |
| Rivaroxaban | Mean Combined Duration of Initial and Subsequent Emergency Department (ED) Hospitalization for Any Reason | Within 90 Days | 0.764 Days | Standard Deviation 2.1829 |
| Standard-of-care | Mean Combined Duration of Initial and Subsequent Emergency Department (ED) Hospitalization for Any Reason | Within 30 Days | 1.513 Days | Standard Deviation 1.9952 |
| Standard-of-care | Mean Combined Duration of Initial and Subsequent Emergency Department (ED) Hospitalization for Any Reason | Within 90 Days | 1.812 Days | Standard Deviation 2.714 |
Secondary
Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire
The Satisfaction to Site-of-Care Questionnaire (standard-of-care versus early discharge on rivaroxaban therapy) was administered after 7 days on anticoagulant therapy. Satisfaction to Site-of-Care (hospitalization versus home care) rates the participant's level of satisfaction to care and location with care received as well as preference to location of care provided. Participants rated the 3 items of this scale of 1=Very satisfied; 2=Quite satisfied; 3=Neither; 4=Quite dissatisfied; and 5=Very dissatisfied for satisfaction questions and for the 1 preference question responses included 1=In the hospital; 2=In the community; and 3=No preference. Higher score indicates more level of satisfaction.
Time frame: Day 7
Population: The safety population included all randomized participants who took at least 1 dose of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Rivaroxaban | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Satisfaction level: Neither | 4.2 Percentage of participants |
| Rivaroxaban | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Location of care: Neither | 4.2 Percentage of participants |
| Rivaroxaban | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Satisfaction level: Very Dissatisfied | 0 Percentage of participants |
| Rivaroxaban | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Location of care: Quite Dissatisfied | 0 Percentage of participants |
| Rivaroxaban | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Satisfaction level: Quite Satisfied | 33.3 Percentage of participants |
| Rivaroxaban | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Location of care: Very Dissatisfied | 0 Percentage of participants |
| Rivaroxaban | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Location of care: Very Satisfied | 62.5 Percentage of participants |
| Rivaroxaban | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Preference of care: In the Hospital | 18.8 Percentage of participants |
| Rivaroxaban | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Satisfaction level: Quite Dissatisfied | 2.1 Percentage of participants |
| Rivaroxaban | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Preference of care: In the Community | 50 Percentage of participants |
| Rivaroxaban | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Location of care: Quite Satisfied | 33.3 Percentage of participants |
| Rivaroxaban | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Preference of care: No Preference | 31.3 Percentage of participants |
| Rivaroxaban | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Satisfaction level: Very Satisfied | 60.4 Percentage of participants |
| Standard-of-care | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Preference of care: No Preference | 11.9 Percentage of participants |
| Standard-of-care | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Satisfaction level: Very Satisfied | 62.7 Percentage of participants |
| Standard-of-care | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Satisfaction level: Quite Satisfied | 23.7 Percentage of participants |
| Standard-of-care | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Satisfaction level: Neither | 6.8 Percentage of participants |
| Standard-of-care | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Satisfaction level: Quite Dissatisfied | 5.1 Percentage of participants |
| Standard-of-care | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Satisfaction level: Very Dissatisfied | 1.7 Percentage of participants |
| Standard-of-care | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Location of care: Very Satisfied | 59.3 Percentage of participants |
| Standard-of-care | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Location of care: Quite Satisfied | 30.5 Percentage of participants |
| Standard-of-care | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Location of care: Neither | 6.8 Percentage of participants |
| Standard-of-care | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Location of care: Quite Dissatisfied | 1.7 Percentage of participants |
| Standard-of-care | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Location of care: Very Dissatisfied | 1.7 Percentage of participants |
| Standard-of-care | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Preference of care: In the Hospital | 47.5 Percentage of participants |
| Standard-of-care | Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire | Preference of care: In the Community | 40.7 Percentage of participants |
Secondary
Percentage of Participants With Number of Unplanned Hospital Visits or Physician Office for VTE Symptoms and/or Bleeding
Percentage of participants of unplanned hospitalization for VTE symptoms or bleeding-related hospital or physician visits were analyzed.
Time frame: Up to 7, 14, 30 and 90 Days
Population: The ITT included all participants who were randomized into the study.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Rivaroxaban | Percentage of Participants With Number of Unplanned Hospital Visits or Physician Office for VTE Symptoms and/or Bleeding | Up to 7 Days | 0 Percentage of Participants |
| Rivaroxaban | Percentage of Participants With Number of Unplanned Hospital Visits or Physician Office for VTE Symptoms and/or Bleeding | Up to 14 Days | 2 Percentage of Participants |
| Rivaroxaban | Percentage of Participants With Number of Unplanned Hospital Visits or Physician Office for VTE Symptoms and/or Bleeding | Up to 30 Days | 3.9 Percentage of Participants |
| Rivaroxaban | Percentage of Participants With Number of Unplanned Hospital Visits or Physician Office for VTE Symptoms and/or Bleeding | Up to 90 Days | 3.9 Percentage of Participants |
| Standard-of-care | Percentage of Participants With Number of Unplanned Hospital Visits or Physician Office for VTE Symptoms and/or Bleeding | Up to 90 Days | 6.3 Percentage of Participants |
| Standard-of-care | Percentage of Participants With Number of Unplanned Hospital Visits or Physician Office for VTE Symptoms and/or Bleeding | Up to 7 Days | 0 Percentage of Participants |
| Standard-of-care | Percentage of Participants With Number of Unplanned Hospital Visits or Physician Office for VTE Symptoms and/or Bleeding | Up to 30 Days | 1.6 Percentage of Participants |
| Standard-of-care | Percentage of Participants With Number of Unplanned Hospital Visits or Physician Office for VTE Symptoms and/or Bleeding | Up to 14 Days | 0 Percentage of Participants |
Secondary
Percentage of Participants With Reoccurrence of Symptomatic Venous Thromboembolism Event (VTE) (Composite of Recurrent PE, New or Recurrent DVT) or VTE-related Death
Reoccurrence of symptomatic, objectively confirmed VTE, defined as recurrent pulmonary embolism (PE) or new or recurrent deep vein thrombosis (DVT) (including symptomatic upper extremity DVT) or VTE related death were analyzed.
Time frame: Up to 7, 14, 30, and 90 Days
Population: The ITT included all participants who were randomized into the study.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Rivaroxaban | Percentage of Participants With Reoccurrence of Symptomatic Venous Thromboembolism Event (VTE) (Composite of Recurrent PE, New or Recurrent DVT) or VTE-related Death | Up to 7 Days | 0 Percentage of participants |
| Rivaroxaban | Percentage of Participants With Reoccurrence of Symptomatic Venous Thromboembolism Event (VTE) (Composite of Recurrent PE, New or Recurrent DVT) or VTE-related Death | Up to 14 Days | 0 Percentage of participants |
| Rivaroxaban | Percentage of Participants With Reoccurrence of Symptomatic Venous Thromboembolism Event (VTE) (Composite of Recurrent PE, New or Recurrent DVT) or VTE-related Death | Up to 30 Days | 0 Percentage of participants |
| Rivaroxaban | Percentage of Participants With Reoccurrence of Symptomatic Venous Thromboembolism Event (VTE) (Composite of Recurrent PE, New or Recurrent DVT) or VTE-related Death | Up to 90 Days | 0 Percentage of participants |
| Standard-of-care | Percentage of Participants With Reoccurrence of Symptomatic Venous Thromboembolism Event (VTE) (Composite of Recurrent PE, New or Recurrent DVT) or VTE-related Death | Up to 90 Days | 0 Percentage of participants |
| Standard-of-care | Percentage of Participants With Reoccurrence of Symptomatic Venous Thromboembolism Event (VTE) (Composite of Recurrent PE, New or Recurrent DVT) or VTE-related Death | Up to 7 Days | 0 Percentage of participants |
| Standard-of-care | Percentage of Participants With Reoccurrence of Symptomatic Venous Thromboembolism Event (VTE) (Composite of Recurrent PE, New or Recurrent DVT) or VTE-related Death | Up to 30 Days | 0 Percentage of participants |
| Standard-of-care | Percentage of Participants With Reoccurrence of Symptomatic Venous Thromboembolism Event (VTE) (Composite of Recurrent PE, New or Recurrent DVT) or VTE-related Death | Up to 14 Days | 0 Percentage of participants |
Secondary
Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS)
ACTS is defined as a validated measure for assessing treatment satisfaction. The ACTS comprised of 2 subscales: Burdens (13 items: Item 1 to 13 \[how much of limitation from taking part in vigorous physical activities, limitation from usual activities, bothered by bruising, bothered to avoid other medicines, limitation to diet, daily hassle, occasional hassle, difficult to follow treatment, time-consuming, worrying, frustrating, burden, negative impact on life respectively) and Benefits (4 items: Items 14 to 17 for evaluating confidence, reassurance, satisfaction, positive impact respectively) as a result of anti-clot treatment. The treatment experience scores ranged from 'Not at all' to 'Extremely' on a 5-point Likert scale (psychometric rating); higher scores indicate greater satisfaction with treatment.
Time frame: Day 90
Population: The safety population included all randomized participants who took at least 1 dose of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 5: A little | 17.8 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 4: Not at all | 60 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 4: A little | 33.3 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 4: Moderately | 4.4 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 4: Quite a bit | 2.2 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 4: Extremely | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 5: Not at all | 80 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 5: Moderately | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 5: Quite a bit | 2.2 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 5: Extremely | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 6: Not at all | 75.6 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 6: A little | 20 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 6: Moderately | 2.2 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 6: Quite a bit | 2.2 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 6: Extremely | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 7: Not at all | 73.3 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 7: A little | 22.2 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 7: Moderately | 4.4 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 7: Quite a bit | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 7: Extremely | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 8: Not at all | 82.2 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 8: A little | 15.6 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 8: Moderately | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 8: Quite a bit | 2.2 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 8: Extremely | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 9: Not at all | 84.4 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 9: A little | 15.6 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 9: Moderately | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 9: Quite a bit | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 9: Extremely | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 10: Not at all | 48.9 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 10: A little | 28.9 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 10: Moderately | 8.9 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 10: Quite a bit | 11.1 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 10: Extremely | 2.2 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 11: Not at all | 77.8 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 11: A little | 17.8 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 11: Moderately | 4.4 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 11: Quite a bit | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 11: Extremely | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 12: Not at all | 84.4 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 12: A little | 15.6 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 12: Moderately | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 12: Quite a bit | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 12: Extremely | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 13: Not at all | 64.4 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 13: A little | 28.9 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 13: Moderately | 4.4 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 13: Quite a bit | 2.2 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 13: Extremely | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 14: Not at all | 4.4 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 14: A little | 8.9 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 14: Moderately | 20 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 14: Quite a bit | 26.7 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 14: Extremely | 40 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 15: Not at all | 4.4 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 15: A little | 8.9 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 15: Moderately | 20 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 15: Quite a bit | 35.6 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 15: Extremely | 31.1 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 16: Not at all | 8.9 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 16: A little | 2.2 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 16: Moderately | 15.6 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 16: Quite a bit | 33.3 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 16: Extremely | 40 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 17: Not at all | 2.2 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 17: A little | 13.3 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 17: Moderately | 17.8 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 17: Quite a bit | 28.9 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 17: Extremely | 37.8 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 1: Not at all | 51.1 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 1: A little | 40 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 1: Moderately | 6.7 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 1: Quite a bit | 2.2 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 1: Extremely | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 2: Not at all | 77.8 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 2: A little | 13.3 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 2: Moderately | 6.7 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 2: Quite a bit | 2.2 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 2: Extremely | 0 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 3: Not at all | 71.1 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 3: A little | 22.2 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 3: Moderately | 2.2 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 3: Quite a bit | 4.4 Percentage of participants |
| Rivaroxaban | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 3: Extremely | 0 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 1: Quite a bit | 1.8 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 5: A little | 16.4 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 3: Extremely | 1.8 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 12: Moderately | 9.3 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 4: Not at all | 52.7 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 16: Quite a bit | 45.5 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 4: A little | 20 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 12: Quite a bit | 3.7 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 4: Moderately | 9.1 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 3: A little | 21.8 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 4: Quite a bit | 10.9 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 12: Extremely | 3.7 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 4: Extremely | 7.3 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 16: Extremely | 30.9 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 5: Not at all | 60 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 13: Not at all | 54.5 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 5: Moderately | 16.4 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 1: Extremely | 3.6 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 5: Quite a bit | 7.3 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 13: A little | 18.2 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 5: Extremely | 0 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 17: Not at all | 7.3 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 6: Not at all | 56.4 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 13: Moderately | 14.5 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 6: A little | 25.5 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 2: Extremely | 1.8 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 6: Moderately | 5.5 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 13: Quite a bit | 7.3 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 6: Quite a bit | 12.7 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 17: A little | 7.3 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 6: Extremely | 0 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 13: Extremely | 5.5 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 7: Not at all | 45.5 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 2: Not at all | 70.9 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 7: A little | 30.9 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 14: Not at all | 5.5 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 7: Moderately | 20 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 17: Moderately | 18.2 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 7: Quite a bit | 1.8 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 14: A little | 7.3 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 7: Extremely | 1.8 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 3: Quite a bit | 5.5 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 8: Not at all | 78.2 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 14: Moderately | 21.8 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 8: A little | 12.7 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 17: Quite a bit | 43.6 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 8: Moderately | 7.3 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 14: Quite a bit | 38.2 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 8: Quite a bit | 1.8 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 2: A little | 20 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 8: Extremely | 0 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 14: Extremely | 27.3 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 9: Not at all | 74.5 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 17: Extremely | 23.6 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 9: A little | 21.8 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 15: Not at all | 5.6 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 9: Moderately | 1.8 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 3: Not at all | 65.5 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 9: Quite a bit | 1.8 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 15: A little | 5.6 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 9: Extremely | 0 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 1: Not at all | 61.8 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 10: Not at all | 43.6 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 15: Moderately | 24.1 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 10: A little | 16.4 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 2: Moderately | 7.3 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 10: Moderately | 18.2 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 15: Quite a bit | 42.6 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 10: Quite a bit | 10.9 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 1: A little | 21.8 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 10: Extremely | 10.9 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 15: Extremely | 22.2 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 11: Not at all | 60 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 3: Moderately | 5.5 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 11: A little | 16.4 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 16: Not at all | 5.5 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 11: Moderately | 7.3 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 1: Moderately | 10.9 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 11: Quite a bit | 9.1 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 16: A little | 9.1 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 11: Extremely | 7.3 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 2: Quite a bit | 0 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 12: Not at all | 64.8 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 16: Moderately | 9.1 Percentage of participants |
| Standard-of-care | Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS) | Item 12: A little | 18.5 Percentage of participants |